A Phase 1b/2 Study of Demcizumab plus Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Demcizumab (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SIERRA
- Sponsors OncoMed Pharmaceuticals
- 16 Sep 2016 Status changed from recruiting to completed.
- 05 Jan 2016 Results from this trial are expected in 2016, according to an OncoMed media release.
- 12 Mar 2015 According to the Oncomed media release, company plans to complete ovarian cancer Phase 1b trial (demcizumab plus paclitaxel) and make go/no-go decision on Phase 2 in this indication in 2015.